3 ·Filed Aug 12, 2026

MLYS

Mineralys Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed1mo ago SEC0001933414-26-000119
Form 3 — initial insider ownership statement
Actionable Insight • Neutral

This is a routine Form 3 filing for a new officer. No trading signal or material event. Monitor for future Form 4 filings that may disclose insider transactions.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
MLYS ▲ +8.09% at T+20d
NEUTRAL call ✓ call won +8.09% · α vs SPY +9.83% · entry $26.09 → $28.20
Next anchor: T+60d in 5w
Latest observation: T+34 +3.25% FF3 residual α
Entry anchored
Aug 12, 2026
via day open
T+1d
-1.72%
call -1.72% · α -1.53%
$25.64
settled 7w ago
T+5d
-1.30%
call -1.30% · α +0.66%
$25.75
settled 6w ago
T+20d
+8.09%
call +8.09% · α +9.83%
$28.20
settled 22d ago
T+60d
—
call — · α —
—
in 5w

Price Chart

Loading chart...

Executive Summary

James J. Ferguson III filed an initial statement of beneficial ownership (Form 3) with the SEC, disclosing his appointment as Chief Medical Officer of Mineralys Therapeutics. The filing is a routine administrative requirement for new officers and contains no financial data, trading activity, or material corporate events.

Key Facts

  • James J. Ferguson III filed a Form 3 as a new reporting owner of Mineralys Therapeutics.
  • Ferguson is listed as Chief Medical Officer of the company.
  • The filing includes a Power of Attorney authorizing others to file Section 16 reports on his behalf.
  • No beneficial ownership amounts or securities transactions are disclosed in the filing.

Financial Impact

No financial impact — the filing is an initial ownership statement with no disclosed holdings or transactions.

Risk Factors

  • No material risks identified from this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (16 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
3 Filing (Primary)0001933414-26-000119
Document: 0001933414-26-000119-index-headers.html0001933414-26-000119
Document: 0001933414-26-000119-index.html0001933414-26-000119
Document: 0001933414-26-000119.txt0001933414-26-000119
22 reports for MLYS
Performance horizon
67% Hit rate 4 of 6 directional calls best @ T+20▲ +20.97%Jun 11, 2026
Filters
Rows
Reports for MLYS — sortable, filterable
TypeNow
Aug 12, 2026
7w ago
3
NEUTRAL ★ 2/10
$26.09 $28.20▲ +8.09%▲ +9.83%$23.56 (−9.70%)
Jul 23, 2026
10w ago
Insider Cluster
NEUTRAL ★ 2/10
$26.71 $25.65▼ −3.97%▼ −7.59%$23.56 (−11.79%)
Jul 21, 2026
10w ago
Insider Cluster
NEUTRAL ★ 3/10
$27.52 $26.61▼ −3.31%▼ −5.87%$23.56 (−14.39%)
Jul 16, 2026
11w ago
Insider Cluster
NEUTRAL ★ 3/10
$27.08 $26.09▼ −3.66%▼ −7.27%$23.56 (−13.00%)
Jun 30, 2026
13w ago
144
NEUTRAL ★ 3/10
$26.89 $26.35▼ −2.01%▲ +0.18%$23.56 (−12.38%)
Jun 29, 2026
13w ago
144
NEUTRAL ★ 3/10
$26.88 $26.71▼ −0.63%▼ −0.35%$23.56 (−12.35%)
Jun 18, 2026
15w ago
Insider Cluster
NEUTRAL ★ 2/10
$24.63 $27.08▲ +9.95%▲ +9.41%$23.56 (−4.34%)
Jun 17, 2026
15w ago
144
NEUTRAL ★ 2/10
$24.63 $27.08▲ +9.95%▲ +9.41%$23.56 (−4.34%)
Jun 11, 2026
16w ago
Institutional Cluster
BULLISH ★ 6/10
$23.94 $28.96▲ +20.97%▲ +19.08%$23.56 (−1.59%)
Jun 3, 2026
17w ago
8-K
MIXED ★ 7/10
$25.06 $27.69▲ +10.49%▲ +11.49%$23.56 (−5.99%)
Showing 10 of 22

US Market Status

Market Open — Closes in 3h 44m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access